Prescription medications Levaquin, Cipro, and Avelox are involved in hundreds of product liability claims that continue to move forward in a multidistrict litigation (MLD) currently underway in the U.S. District Court for the District of Minnesota.
The Court has granted a plaintiff’s motion that sought to amend the Master Complaint to reflect the U.S. Food and Drug Administration’s (FDA) safety announcement in May 2016 regarding fluoroquinolone antibiotics.
A number of patients were allegedly injured by Levaquin as well as other fluoroquinolone antibiotics. Some patients were diagnosed with peripheral neuropathy that may be associated with the use of Levaquin, Cipro, or Avelox.
Levaquin, Cipro, and Avelox all are part of a class of antibiotics known as fluoroquinolones. These medications are meant to treat serious bacterial infection such as pneumonia, staph, and sexually transmitted diseases.
The FDA ordered all fluoroquinolone manufacturers to update the antibiotics
In May, 2016, the FDA ordered all fluoroquinolone manufacturers to update the antibiotics’ boxed warning to state that the risks posed by the drugs may outweigh their benefits for patients with specific uncomplicated infections when other treatment options are available.
Serious side effects associated with numerous problems include issues with tendons, muscles, joint, nerves and the central nervous system. These complications are possibly permanent and can occur together, according to the FDA.
Peripheral neuropathy is a serious nerve disorder that can lead to permanent disability. There are at least 484 peripheral neuropathy lawsuits involving Levaquin, Cipro and Avelox pending in the U.S. District Court for the District of Minnesota according to the Minutes from the June 21st Status Conference.